Overview

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Status:
Recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.

Phase:

Phase 4

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Collaborator:

Bausch Health Americas, Inc.

Treatments:

Halobetasol
Tazarotene